 |
|
VIGNETTES
Sunitinib: A Cause of Bullous Palmoplantar Erythrodysesthesia, Periungual Erythema, and Mucositis
Pitiporn Suwattee, MD, FRCPC;
Steven Chow, MD, MS;
Brian C. Berg, MD;
Erin M. Warshaw, MD, MS
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Sunitinib (SU011248) (Sutent; Pfizer Inc, New York, New York) is an oral multikinase phosphorylation inhibitor of receptor tyrosine kinases (RTKs), which are implicated in tumor growth, angiogenesis, and metastasis of cancer. Although it is approved for use in the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma, sunitinib has also been shown to be efficacious in treating neuroendocrine, colon, and breast cancers.1 Dermatologic adverse effects include rash, skin discoloration, hair color changes, xerosis, alopecia, and seborrheic dermatitis–like reactions.2 Palmoplantar erythrodysesthesia (PPE) was reported in 12% to 14% of patients in large phase 2 and 3 studies.3 To our knowledge, we describe herein the first case of sunitinib-related intense periungual erythema and severe mucositis in addition to bullous PPE.
Report of a Case
A 59-year-old man was seen for tender erythema and swelling of the . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Drug-induced cutaneous pathology
Ramdial and Naidoo
J. Clin. Pathol. 2009;62:493-504.
ABSTRACT
| FULL TEXT
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Lacouture et al.
The Oncologist 2008;13:1001-1011.
ABSTRACT
| FULL TEXT
Palmar-Plantar Erythrodysesthesia Secondary to Sunitinib Treatment Resulting in Necrotic Foot Syndrome Aggravated by Background Diabetic Vascular Disease
Guenova et al.
Arch Dermatol 2008;144:1081-1082.
FULL TEXT
|
